MedTrace Logo

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke

NCT02829502 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-03-03

No results posted yet for this study

Summary

This randomized controlled trial investigates the effect of a single dose of glucagon-like peptide-1 (GLP-1) receptor agonist in the subacute phase of stroke in humans. The primary endpoint is the mean flow velocity in the middle cerebral arteries measured by transcranial doppler and cortical oxygination measured by near infrared spectroscopy (NIRS). The secondary endpoints are changes in endothelial/inflammatory biomarkers in the blood, changes in the ankle-brachial index and changes in the reactive hyperaemia index measured by EndoPAT2000.

Conditions

Interventions

DRUG

Byetta

Single dose of subcutaneous injection of 5 μg exenatide (Byetta).

DRUG

Normosaline

Single dose of subcutaneous injection of 20 μL normosaline (placebo).

Sponsors & Collaborators

  • Christina Kruuse

    lead OTHER

Principal Investigators

  • Christina R Kruuse, MD,PhD · Study Principal Investigator, Consultant Neurologist, Dept. Neurology, Herlev Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2023-08-31
Completion
2023-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02829502 on ClinicalTrials.gov